Southeastern Grocers Donates $395,000 to Children’s Hospitals Across the Southeast

Grocer and customers show support for pediatric care facilities during National Cancer Research Month JACKSONVILLE, Fla.–(BUSINESS WIRE)–Southeastern Grocers Inc. (SEG), parent company and home of Fresco y Más, Harveys Supermarket and Winn-Dixie grocery stores, announces a donation of $395,000 to nine children’s hospitals across the Southeast. In recognition of National Cancer Research Month, SEG’s generous … [Read more…]

Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at:, is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes … [Read more…]

Breakthrough Medical Advance Known as the PossoverTM LION Procedure Helps Paraplegics Walk Again and Gives Hope to Many More

— New medical procedure is the first and only therapeutic method in the world resulting in the recovery of voluntary walking in 70 percent of incomplete and complete paraplegics — –(BUSINESS WIRE)–Possover International Medical Center: WHAT: A revolutionary new medical advance called the PossoverTM LION Procedure is helping improve the mobility and quality of life … [Read more…]

Global Mammography Market Report to 2030 – Featuring Carestream Health, Konica Minolta and Hologic Among Others –

DUBLIN–(BUSINESS WIRE)–The “Global Mammography Market Outlook 2020-2030” report has been added to’s offering. The global mammography market is anticipated to grow with a CAGR of 8.61% over the forecast period, i.e., 2021 – 2030. The global mammography market is estimated to garner a revenue of near to USD 4530 Million by the end of … [Read more…]

Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows

MANHASSET, N.Y.–(BUSINESS WIRE)–A phase two clinical trial has shown the efficacy of famotidine, commonly known as Pepcid, in alleviating coronavirus disease 2019 (COVID-19) symptoms in adult patients. In a new study, scientists at The Feinstein Institutes for Medical Research discovered this widely used heartburn medication stimulates the vagus nerve, which suppresses cytokine storm – a … [Read more…]

MeMD Unveils Name Change to Walmart Health Virtual Care

MeMD marks official transition to Walmart Health family following its acquisition in 2021 SCOTTSDALE, Ariz.–(BUSINESS WIRE)–MeMD, a multi-specialty national telehealth provider, today announced its name change to Walmart Health Virtual Care as part of its official transition to the Walmart Health family. The name change marks the final stages of MeMD’s acquisition by Walmart Health, … [Read more…]

Global Blood Testing Market Forecast to 2029 – Featuring Abbott Laboratories, bioMerieux and Grifols Among Others –

DUBLIN–(BUSINESS WIRE)–The “Global Blood Testing Market, Forecast to 2029” report has been added to’s offering. The Blood Testing Market is expected to witness a CAGR of 5.4% during the forecast period. This report focuses on the Blood Testing market revenue at the global, regional, and company levels. From a global perspective, this report represents … [Read more…]

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

LOS ANGELES–(BUSINESS WIRE)–Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Eisai has ended the evaluation of eritoran in the REMAP-COVID study. Eritoran, an investigational TLR-4 antagonist discovered and developed by Eisai, was selected for evaluation because it was hypothesized to suppress the over-production and release of various pro-inflammatory mediators (“cytokine storm”) … [Read more…]

Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors

— TAC-001 will be the First Candidate from Tallac’s Novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) Platform to Enter Clinical Trials — TAC-001 Integrates B cells and TLR9 Activation to Trigger Innate and Adaptive Anti-tumor Immune Responses — Tallac Plans to Initiate a Phase 1/2 Clinical Study of Systemically Administered TAC-001 for Patients with Advanced … [Read more…]